| Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors J Strosberg, G El-Haddad, E Wolin, A Hendifar, J Yao, B Chasen, E Mittra, ... New England Journal of Medicine 376 (2), 125-135, 2017 | 3096 | 2017 |
| Carcinoid tumors MH Kulke, RJ Mayer New England Journal of Medicine 340 (11), 858-868, 1999 | 1245 | 1999 |
| Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study JC Yao, N Fazio, S Singh, R Buzzoni, C Carnaghi, E Wolin, J Tomasek, ... The Lancet 387 (10022), 968-977, 2016 | 1241 | 2016 |
| Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial JC Yao, C Lombard-Bohas, E Baudin, LK Kvols, P Rougier, ... Journal of clinical oncology 28 (1), 69-76, 2010 | 803 | 2010 |
| Activity of sunitinib in patients with advanced neuroendocrine tumors MH Kulke, HJ Lenz, NJ Meropol, J Posey, DP Ryan, J Picus, E Bergsland, ... Journal of Clinical Oncology 26 (20), 3403-3410, 2008 | 768 | 2008 |
| NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas MH Kulke, LB Anthony, DL Bushnell, WW De Herder, SJ Goldsmith, ... Pancreas 39 (6), 735-752, 2010 | 709 | 2010 |
| Consensus guidelines for the management and treatment of neuroendocrine tumors PL Kunz, D Reidy-Lagunes, LB Anthony, EM Bertino, K Brendtro, JA Chan, ... Pancreas 42 (4), 557-577, 2013 | 669 | 2013 |
| Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors MH Kulke, K Stuart, PC Enzinger, DP Ryan, JW Clark, A Muzikansky, ... Journal of Clinical Oncology 24 (3), 401-406, 2006 | 620 | 2006 |
| PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot, RH Jones, H Eng, ... Molecular cancer 22 (1), 138, 2023 | 570 | 2023 |
| Cancer susceptibility gene mutations in individuals with colorectal cancer MB Yurgelun, MH Kulke, CS Fuchs, BA Allen, H Uno, JL Hornick, ... Journal of Clinical Oncology 35 (10), 1086-1095, 2017 | 546 | 2017 |
| Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing J Li, L Wang, H Mamon, MH Kulke, R Berbeco, GM Makrigiorgos Nature medicine 14 (5), 579-584, 2008 | 511 | 2008 |
| Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set DS Klimstra, IR Modlin, NV Adsay, R Chetty, V Deshpande, M Gönen, ... The American journal of surgical pathology 34 (3), 300-313, 2010 | 464 | 2010 |
| O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors MH Kulke, JL Hornick, C Frauenhoffer, S Hooshmand, DP Ryan, ... Clinical Cancer Research 15 (1), 338-345, 2009 | 449 | 2009 |
| Neuroendocrine tumors, version 1.2015 MH Kulke, MH Shah, AB Benson, E Bergsland, JD Berlin, LS Blaszkowsky, ... Journal of the National Comprehensive Cancer Network 13 (1), 78-108, 2015 | 418 | 2015 |
| Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, RP Baum, ... Journal of Clinical Oncology 36 (25), 2578-2584, 2018 | 407 | 2018 |
| The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas JR Strosberg, D Coppola, DS Klimstra, AT Phan, MH Kulke, GA Wiseman, ... Pancreas 39 (6), 799-800, 2010 | 398 | 2010 |
| Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, ... British journal of cancer 101 (3), 465-472, 2009 | 386 | 2009 |
| Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting MH Kulke, LL Siu, JE Tepper, G Fisher, D Jaffe, DG Haller, LM Ellis, ... Journal of Clinical oncology 29 (7), 934-943, 2011 | 368 | 2011 |
| Somatic mutation of CDKN1B in small intestine neuroendocrine tumors JM Francis, A Kiezun, AH Ramos, S Serra, CS Pedamallu, ZR Qian, ... Nature genetics 45 (12), 1483-1486, 2013 | 363 | 2013 |
| Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome MH Kulke, D Hörsch, ME Caplin, LB Anthony, E Bergsland, K Öberg, ... Journal of clinical oncology 35 (1), 14-23, 2017 | 361 | 2017 |
